Free Trial

ZimVie (ZIMV) Competitors

ZimVie logo
$18.88 +0.03 (+0.13%)
As of 01:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ZIMV vs. EYE, LMAT, CNMD, LQDA, ENOV, AORT, CDRE, NVCR, SSII, and ESTA

Should you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include National Vision (EYE), LeMaitre Vascular (LMAT), CONMED (CNMD), Liquidia Technologies (LQDA), Enovis (ENOV), Artivion (AORT), Cadre (CDRE), NovoCure (NVCR), SS Innovations International (SSII), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry.

ZimVie vs. Its Competitors

National Vision (NASDAQ:EYE) and ZimVie (NASDAQ:ZIMV) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

National Vision has a net margin of -0.75% compared to ZimVie's net margin of -4.39%. ZimVie's return on equity of 6.37% beat National Vision's return on equity.

Company Net Margins Return on Equity Return on Assets
National Vision-0.75% 3.56% 1.49%
ZimVie -4.39%6.37%3.34%

In the previous week, National Vision had 15 more articles in the media than ZimVie. MarketBeat recorded 16 mentions for National Vision and 1 mentions for ZimVie. ZimVie's average media sentiment score of 1.87 beat National Vision's score of 1.02 indicating that ZimVie is being referred to more favorably in the news media.

Company Overall Sentiment
National Vision Positive
ZimVie Very Positive

National Vision currently has a consensus target price of $24.73, suggesting a potential upside of 5.44%. ZimVie has a consensus target price of $17.75, suggesting a potential downside of 5.96%. Given National Vision's stronger consensus rating and higher possible upside, equities research analysts plainly believe National Vision is more favorable than ZimVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
National Vision
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60
ZimVie
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

National Vision has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, ZimVie has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500.

95.6% of ZimVie shares are owned by institutional investors. 2.7% of National Vision shares are owned by company insiders. Comparatively, 5.4% of ZimVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ZimVie has lower revenue, but higher earnings than National Vision. National Vision is trading at a lower price-to-earnings ratio than ZimVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Vision$1.89B0.99-$28.50M-$0.18-130.29
ZimVie$449.75M1.18-$25.83M-$0.70-26.96

Summary

ZimVie beats National Vision on 9 of the 16 factors compared between the two stocks.

Get ZimVie News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZIMV vs. The Competition

MetricZimVieMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$532.28M$10.64B$5.63B$9.80B
Dividend YieldN/A2.00%4.64%4.14%
P/E Ratio-26.9620.4130.2025.63
Price / Sales1.1824.34463.44105.91
Price / Cash10.1423.7337.7258.50
Price / Book1.293.088.456.05
Net Income-$25.83M$211.77M$3.26B$265.11M
7 Day Performance0.29%8.32%3.22%2.54%
1 Month Performance109.72%9.24%5.66%3.63%
1 Year Performance11.62%-6.52%42.67%26.29%

ZimVie Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZIMV
ZimVie
0.9581 of 5 stars
$18.88
+0.1%
$17.75
-6.0%
+7.7%$532.28M$449.75M-26.961,770Positive News
EYE
National Vision
2.8831 of 5 stars
$25.07
+3.6%
$24.18
-3.5%
+123.2%$1.91B$1.82B-75.9713,411Positive News
Earnings Report
LMAT
LeMaitre Vascular
2.1918 of 5 stars
$84.36
+4.1%
$97.83
+16.0%
+15.0%$1.83B$226.26M42.61490Insider Trade
CNMD
CONMED
3.9498 of 5 stars
$53.46
+2.2%
$59.80
+11.9%
-18.1%$1.62B$1.31B15.153,900Dividend Announcement
LQDA
Liquidia Technologies
2.9771 of 5 stars
$19.48
+10.2%
$26.89
+38.0%
+97.4%$1.51B$14M-12.3350Trending News
Earnings Report
Analyst Forecast
Options Volume
Gap Up
ENOV
Enovis
3.865 of 5 stars
$26.61
+3.4%
$55.60
+109.0%
-32.2%$1.47B$2.11B-1.917,367News Coverage
Earnings Report
Analyst Revision
AORT
Artivion
2.9634 of 5 stars
$32.06
+3.7%
$32.40
+1.1%
+73.9%$1.32B$388.54M-64.121,600Earnings Report
Analyst Downgrade
CDRE
Cadre
3.7938 of 5 stars
$33.09
+2.3%
$37.50
+13.3%
-12.7%$1.31B$567.56M34.832,284News Coverage
Analyst Downgrade
Analyst Revision
Gap Down
NVCR
NovoCure
4.578 of 5 stars
$11.76
+3.9%
$28.79
+144.8%
-38.3%$1.27B$605.22M-7.541,488Positive News
SSII
SS Innovations International
N/A$6.57
+6.0%
N/AN/A$1.20B$20.65M0.004Gap Up
ESTA
Establishment Labs
2.0933 of 5 stars
$42.72
+3.3%
$54.83
+28.4%
-18.1%$1.20B$166.02M-13.781,018Earnings Report

Related Companies and Tools


This page (NASDAQ:ZIMV) was last updated on 8/13/2025 by MarketBeat.com Staff
From Our Partners